Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Eidos Therapeutics Inc. (NASDAQ:EIDX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Reata Pharmaceuticals Inc.||86||94.95||N/A||-3.99||0.00|
|Eidos Therapeutics Inc.||30||0.00||N/A||-1.74||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 has Reata Pharmaceuticals Inc. and Eidos Therapeutics Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Reata Pharmaceuticals Inc.||0.00%||380%||-36.9%|
|Eidos Therapeutics Inc.||0.00%||-22.6%||-21.7%|
Reata Pharmaceuticals Inc. has a Current Ratio of 5.2 and a Quick Ratio of 5.2. Competitively, Eidos Therapeutics Inc.’s Current Ratio is 19 and has 19 Quick Ratio. Eidos Therapeutics Inc.’s better ability to pay short and long-term obligations than Reata Pharmaceuticals Inc.
The Ratings and Recommendations for Reata Pharmaceuticals Inc. and Eidos Therapeutics Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Reata Pharmaceuticals Inc.||0||0||0||0.00|
|Eidos Therapeutics Inc.||0||0||1||3.00|
Reata Pharmaceuticals Inc.’s consensus price target is $185, while its potential upside is 107.98%. Meanwhile, Eidos Therapeutics Inc.’s consensus price target is $33, while its potential downside is -25.51%. The data from earlier shows that analysts opinion suggest that Reata Pharmaceuticals Inc. seems more appealing than Eidos Therapeutics Inc.
Insider & Institutional Ownership
The shares of both Reata Pharmaceuticals Inc. and Eidos Therapeutics Inc. are owned by institutional investors at 69.6% and 35.8% respectively. Reata Pharmaceuticals Inc.’s share owned by insiders are 0.3%. On the other hand, insiders owned about 1.3% of Eidos Therapeutics Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Reata Pharmaceuticals Inc.||0.18%||-5.33%||16.47%||17.7%||29.63%||61.59%|
|Eidos Therapeutics Inc.||-15.13%||0.49%||31.27%||174.94%||87.46%||136.77%|
For the past year Reata Pharmaceuticals Inc. was less bullish than Eidos Therapeutics Inc.
On 5 of the 9 factors Eidos Therapeutics Inc. beats Reata Pharmaceuticals Inc.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.